Weekly Rundown
| 4 min read
Billion-dollar partnerships, Phase 1 wins, AI regulatory tools, and more led the news this week.
| 4 min read
FDA updates, pharma tariff agreements, gene editing deals, and more led the news this week.
| 4 min read
Rare disease approvals, multi-billion-dollar deals, and more led this week’s headlines.
| 4 min read
Greater focus on non-animal testing methods in the UK, a new CRISPR treatment to lower cholesterol, and positive results for a BTK inhibitor in MS led the news this week.
| 4 min read
FDA approvals, rejections, antibody-drug conjugate deals, and more led the news this week.
| 4 min read
Another biotech retreats from AAV, a promising antibiotic, a paused CRISPR trial, and more led the news this week.
| 4 min read
Multibillion dollar oncology deals, first-in-class wins, AI scientists, and more led the news this week.
| 4 min read
Positive results for breast cancer, funding for precision therapies for heart disease, strong results for Lilly’s oral GLP-1, and more led the news this week.
| 4 min read
Positive results for a radioligand therapy, a billion-dollar deal for a MASH drug, the Nobel Prize for immune system research, and more led the news this week.
| 4 min read
An FDA rejection, Takeda restructuring, Trump initiatives and more lead the news this week.
